Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology
Milestone Pharmaceuticals (Nasdaq: MIST) announced it will present a moderated poster at the American College of Cardiology annual meeting (ACC25) in Chicago from March 29-31, 2025. The presentation will focus on clinical data for etripamil, showcasing its potential to convert multiple episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to normal sinus rhythm.
According to Chief Medical Officer Dr. David Bharucha, the data demonstrates that successful conversion of earlier PSVT episodes predicts success in subsequent treatments. The findings support etripamil's potential use for successive PSVT episodes, pending approval, aiming to improve patient experience and quality of life.
Milestone Pharmaceuticals (Nasdaq: MIST) ha annunciato che presenterà un poster moderato al congresso annuale dell'American College of Cardiology (ACC25) a Chicago dal 29 al 31 marzo 2025. La presentazione si concentrerà sui dati clinici per etripamil, evidenziando il suo potenziale nel convertire più episodi di Tachicardia Supraventricolare Parossistica (PSVT) in ritmo sinusale normale.
Secondo il Chief Medical Officer Dr. David Bharucha, i dati dimostrano che la conversione riuscita di episodi PSVT precedenti predice il successo nei trattamenti successivi. I risultati supportano il potenziale utilizzo di etripamil per episodi successivi di PSVT, in attesa di approvazione, con l'obiettivo di migliorare l'esperienza del paziente e la qualità della vita.
Milestone Pharmaceuticals (Nasdaq: MIST) anunció que presentará un póster moderado en la reunión anual del American College of Cardiology (ACC25) en Chicago del 29 al 31 de marzo de 2025. La presentación se centrará en los datos clínicos de etripamil, mostrando su potencial para convertir múltiples episodios de Tacocardia Supraventricular Paroxística (PSVT) en ritmo sinusal normal.
Según el Director Médico Dr. David Bharucha, los datos demuestran que la conversión exitosa de episodios PSVT anteriores predice el éxito en tratamientos posteriores. Los hallazgos respaldan el potencial uso de etripamil para episodios sucesivos de PSVT, pendiente de aprobación, con el objetivo de mejorar la experiencia del paciente y la calidad de vida.
Milestone Pharmaceuticals (Nasdaq: MIST)는 2025년 3월 29일부터 31일까지 시카고에서 열리는 American College of Cardiology 연례 회의(ACC25)에서 조정된 포스터를 발표할 것이라고 발표했습니다. 발표는 etripamil에 대한 임상 데이터를 중심으로, 여러 차례의 발작성 심실상성 빈맥 (PSVT) 에피소드를 정상 동성 리듬으로 전환할 수 있는 잠재력을 강조할 것입니다.
최고 의료 책임자인 Dr. David Bharucha에 따르면, 데이터는 이전 PSVT 에피소드의 성공적인 전환이 이후 치료의 성공을 예측함을 보여줍니다. 이 발견은 etripamil이 승인 대기 중인 연속 PSVT 에피소드를 위한 잠재적 사용을 지원하며, 환자의 경험과 삶의 질을 향상시키는 것을 목표로 하고 있습니다.
Milestone Pharmaceuticals (Nasdaq: MIST) a annoncé qu'il présentera un poster modéré lors de la réunion annuelle du American College of Cardiology (ACC25) à Chicago du 29 au 31 mars 2025. La présentation mettra l'accent sur les données cliniques concernant etripamil, mettant en lumière son potentiel à convertir plusieurs épisodes de Tachycardie Supraventriculaire Paroxystique (PSVT) en rythme sinusal normal.
Selon le directeur médical Dr. David Bharucha, les données démontrent que la conversion réussie des épisodes PSVT antérieurs prédit le succès des traitements ultérieurs. Les résultats soutiennent le potentiel d'utilisation d'etripamil pour des épisodes successifs de PSVT, en attente d'approbation, visant à améliorer l'expérience des patients et la qualité de vie.
Milestone Pharmaceuticals (Nasdaq: MIST) hat angekündigt, dass es auf dem American College of Cardiology Jahresmeeting (ACC25) in Chicago vom 29. bis 31. März 2025 ein moderiertes Poster präsentieren wird. Die Präsentation wird sich auf klinische Daten zu etripamil konzentrieren und dessen Potenzial hervorheben, mehrere Episoden von paroxysmaler supraventrikulärer Tachykardie (PSVT) in einen normalen Sinusrhythmus umzuwandeln.
Laut dem Chief Medical Officer Dr. David Bharucha zeigen die Daten, dass eine erfolgreiche Umwandlung früherer PSVT-Episoden den Erfolg bei nachfolgenden Behandlungen vorhersagt. Die Ergebnisse unterstützen das potenzielle Einsatzgebiet von etripamil für aufeinanderfolgende PSVT-Episoden, vorbehaltlich der Genehmigung, mit dem Ziel, das Patientenerlebnis und die Lebensqualität zu verbessern.
- Clinical data shows positive results for etripamil in treating multiple PSVT episodes
- Early treatment success predicts effectiveness in subsequent episodes
- None.
MONTREAL and CHARLOTTE, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present a moderated poster presentation at the American College of Cardiology annual meeting (ACC25), to be held March 29th to 31st, 2025 in Chicago, Illinois.
“This presentation highlights the potential ability of etripamil to successfully convert multiple episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to restore normal sinus rhythm. Further, the data showed that conversion of earlier episodes was predictive of conversion in subsequent ones,” said David Bharucha, MD PhD FACC, Chief Medical Officer of Milestone Pharmaceuticals. “These new data support the opportunity to use etripamil, if approved, for successive PSVT episodes underscoring a potentially positive impact on patients’ experience and quality of life, in line with Milestone’s commitment to providing a convenient and effective therapeutic option for PSVT.”
| ACC Presentation Details: | |
| Moderated Poster Presentation Title: | Consistency and Predictiveness of Conversion Among Multiple Episodes of Paroxysmal Supraventricular Tachycardia (PSVT) Treated with Etripamil: Outcomes from the NODE-303 trial |
| Presenter: | James Ip, M.D., Associate Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital |
| Date and time: | Sunday, March 30, 2025, 11:42 – 11:49 AM Central Time |
| Location: | Moderated Poster Theater 1 |
A copy of the abstract can be viewed on the ACC25 website, on the Online Planner here.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "continue," "could," "demonstrate," "designed," "develop," "estimate," "expect," "may," "pending," "plan," "potential," "progress," "will", “intend” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the timing and outcomes of future interactions with U.S. and foreign regulatory bodies, including the FDA; the potential of etripamil to (i) successfully convert multiple episodes of PSVT to restore normal sinus rhythm and (ii) have a positive impact on patients’ experience and quality of life; and other statements not related to historical fact. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, whether our future interactions with the FDA will have satisfactory outcomes; whether and when, if at all, our NDA for etripamil will be approved by the FDA; uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of our clinical trials; risks and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications; general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, international tariffs, Russian hostilities in Ukraine and ongoing disputes in Israel and Gaza and overall fluctuations in the financial markets in the United States and abroad; risks related to pandemics and public health emergencies; and risks related the sufficiency of Milestone's capital resources and its ability to raise additional capital in the current economic climate. These and other risks are set forth in Milestone's filings with the U.S. Securities and Exchange Commission, including in its annual report on Form 10-K for the year ended December 31, 2024, under the caption "Risk Factors," as such discussion may be updated from time to time by subsequent filings Milestone may make with the U.S. Securities & Exchange Commission. Except as required by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Contact:
Kim Fox, Vice President, Communications, kfox@milestonepharma.com
Investor Relations: Kevin Gardner, kgardner@lifesciadvisors.com
FAQ
What clinical data will Milestone Pharmaceuticals (MIST) present at ACC25?
When and where will Milestone Pharmaceuticals (MIST) present at the ACC 2025 conference?
What are the key findings of etripamil's clinical data for PSVT treatment?
How could etripamil benefit PSVT patients according to MIST's presentation?
